Immunotherapy trial helps cancer patients with tumours live 40% longer

Experts praise groundbreaking results from therapy using genetically modified Car T-cells Cancer patients treated with a pioneering immunotherapy that genetically modifies their own cells to wipe out tumours live 40% longer, according to “exciting” and “groundbreaking” results from a world-first clinical trial.Car T-cell therapy is a new form of immunotherapy where a patient’s own T-cells – a type of white blood cell – are tweaked in a lab to target and kill cancer cells. The designer cells are then infused back into their bloodstream to fight the disease. Continue reading...

Immunotherapy trial helps cancer patients with tumours live 40% longer

Experts praise groundbreaking results from therapy using genetically modified Car T-cells

Cancer patients treated with a pioneering immunotherapy that genetically modifies their own cells to wipe out tumours live 40% longer, according to “exciting” and “groundbreaking” results from a world-first clinical trial.

Car T-cell therapy is a new form of immunotherapy where a patient’s own T-cells – a type of white blood cell – are tweaked in a lab to target and kill cancer cells. The designer cells are then infused back into their bloodstream to fight the disease.

Continue reading...